Changing Treatment Landscape in the Initial Management of Metastatic Castrate-Resistant Prostate Cancer (mCRPC): An Australian Multi-Centre Retrospective Study

被引：0
|
作者：
Kwan, E. [1 ,2 ]
Semira, C. [3 ,4 ]
Muttiah, C. [5 ]
Beck, S. [3 ,4 ]
Anton, A. [4 ]
Tran, B. [3 ,4 ]
机构：
[1] Monash Hlth, Dept Med Oncol, Melbourne, Vic, Australia
[2] Monash Univ, Sch Clin Sci, Dept Med, Melbourne, Vic, Australia
[3] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[4] Walter & Eliza Hall Inst Med Res, Div Syst Biol & Personalised Med, Melbourne, Vic, Australia
[5] Western Hlth, Dept Med Oncol, Melbourne, Vic, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：48 / 49
页数：2
相关论文
共 50 条
  • [21] Elderly patients with metastatic castrate-resistant prostate cancer (mCRPC): Safety and efficacy of docetaxel retreatment
    Gernone, A.
    Pagliarulo, A.
    Calderoni, G.
    Pagliarulo, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [22] Treatment of castrate-resistant prostate cancer - What is the best management?
    Uemura, Hirotsugu
    Reiter, Robert
    INTERNATIONAL JOURNAL OF UROLOGY, 2015, 22 (04) : 427 - 427
  • [23] Updated analysis of a phase II study using sorafenib (S) for metastatic castrate-resistant prostate cancer (mCRPC)
    Aragon-Ching, J. B.
    Jain, L.
    Draper, D.
    Gulley, J. L.
    Arlen, P. M.
    Wright, J. J.
    Jones, E.
    Chen, C. C.
    Figg, W. D.
    Dahut, W. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer
    Rose, Jim N.
    Crook, Juanita M.
    THERAPEUTIC ADVANCES IN UROLOGY, 2015, 7 (03) : 135 - 145
  • [25] Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer
    Zhang, Jingsong
    Cunningham, Jessica J.
    Brown, Joel S.
    Gatenby, Robert A.
    NATURE COMMUNICATIONS, 2017, 8
  • [26] A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population.
    Karzai, Fatima
    Madan, Ravi Amrit
    Owens, Helen
    Couvillon, Anna
    Hankin, Amy
    Williams, Monique
    Bilusic, Marijo
    Cordes, Lisa M.
    Trepel, Jane B.
    Killian, Keith
    Meltzer, Paul S.
    Gulley, James L.
    Lee, Jung-min
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [27] Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer
    Jingsong Zhang
    Jessica J. Cunningham
    Joel S. Brown
    Robert A. Gatenby
    Nature Communications, 8
  • [28] Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer
    Wissing, Michel D.
    van Diest, Paul J.
    van der Wall, Elsken
    Gelderblom, Hans
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (05) : 635 - 661
  • [29] Analysis of the prognostic significance of circulating tumor DNA (ctDNA) in metastatic castrate-resistant prostate cancer (mCRPC)
    Shaya, Justin
    Randall, James Michael
    Millard, Frederick E.
    Kurzrock, Razelle
    Parsons, J. Kellogg
    Tamayo, Pablo
    McKay, Rana R.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [30] Cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
    Karzai, Fatima
    Madan, Ravi Amrit
    Theoret, Marc Robert
    Arlen, Philip M.
    Dawson, Nancy Ann
    Rosner, Inger L.
    McLeod, David G.
    Wright, John Joseph
    Cordes, Lisa M.
    Couvillon, Anna
    Chun, Guinevere
    Harold, Nancy
    Steinberg, Seth M.
    Trepel, Jane B.
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
12345